Brief: Innate Pharma: positive set of first data from TELLOMAK

Innate Pharma SA

22/06/2021 12:03

June 22 (Reuters) - Innate Pharma SA  IPH.PA :
    * REG-INNATE PHARMA PRESENTS PRELIMINARY DATA FROM TELLOMAK
TRIAL
SHOWING CLINICAL RESPONSE FOR LACUTAMAB IN MYCOSIS FUNGOIDES
    * REG-INNATE PHARMA PRESENTS PRELIMINARY DATA FROM TELLOMAK
TRIAL
SHOWING CLINICAL RESPONSE FOR LACUTAMAB IN MYCOSIS FUNGOIDES
    * DATA SUPPORT CONTINUED DEVELOPMENT OF LACUTAMABFOR
KIR3DL2-EXPRESSING T-CELL LYMPHOMAS
    * DATA SUPPORT CONTINUED DEVELOPMENT OF LACUTAMAB FOR
KIR3DL2-EXPRESSING T-CELL LYMPHOMAS
    * FIRST DATA SET FROM TELLOMAK ESTABLISHES SAFETY, CLINICAL
RESPONSES AND SKIN IMPROVEMENT IN PATIENTS WITH MYCOSIS
FUNGOIDES THAT EXPRESS KIR3DL2
    * LACUTAMAB DEMONSTRATED CLINICAL RESPONSES IN PATIENTS WITH
MF
THAT EXPRESS KIR3DL2 (COHORT 2), REACHING PRE-DETERMINED
THRESHOLD TO ADVANCE TO STAGE 2

Source text for Eikon:  ID:nGNE5gyQF2 
Further company coverage:  IPH.PA 

 (Reporting by Sudip Kar-Gupta)
 ((sudip.kargupta@thomsonreuters.com;))